

**CCNB2 Antibody (Center) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP2851c****Specification**

---

**CCNB2 Antibody (Center) Blocking Peptide - Product Information**Primary Accession [O95067](#)**CCNB2 Antibody (Center) Blocking Peptide - Additional Information****Gene ID** 9133**Other Names**

G2/mitotic-specific cyclin-B2, CCNB2

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP2851c](/products/AP2851c) was selected from the Center region of human CCNB2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**CCNB2 Antibody (Center) Blocking Peptide - Protein Information****Name** CCNB2**Function**

Essential for the control of the cell cycle at the G2/M (mitosis) transition.

**CCNB2 Antibody (Center) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**CCNB2 Antibody (Center) Blocking Peptide - Images****CCNB2 Antibody (Center) Blocking Peptide - Background**

Cyclin B2 is a member of the cyclin family, specifically the B-type cyclins. The B-type cyclins, B1 and B2, associate with p34cdc2 and are essential components of the cell cycle regulatory machinery. B1 and B2 differ in their subcellular localization. Cyclin B1 co-localizes with microtubules, whereas cyclin B2 is primarily associated with the Golgi region. Cyclin B2 also binds to transforming growth factor beta RII and thus cyclin B2/cdc2 may play a key role in transforming growth factor beta-mediated cell cycle control.

#### **CCNB2 Antibody (Center) Blocking Peptide - References**

De Martino, I., Cancer Res. 69 (5), 1844-1850 (2009) Bellanger, S., Oncogene 26 (51), 7175-7184 (2007)